Clicky

Fulcrum Therapeutics, Inc.(FULC)

Description: Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that are developing for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-HbF, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and b-thalassemia. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.


Keywords: Medicine Biopharmaceutical Disease Disorders Disability Dystrophy Infancy Muscular Dystrophy Hemoglobin Progressive Sickle Cell Disease Thalassemia Facioscapulohumeral Muscular Dystrophy

Home Page: www.fulcrumtx.com

FULC Technical Analysis

26 Landsdowne Street
Cambridge, MA 02139
United States
Phone: 617 651 8851


Officers

Name Title
Mr. Bryan E. Stuart Pres, CEO & Director
Dr. Judith A. Dunn Ph.D. Interim Chief Medical Officer
Dr. Bradley E. Bernstein M.D., Ph.D. Founder
Dr. Michael R. Green Founder
Dr. Rudolf Jaenisch M.D., Ph.D. Founder
Prof. Jeannie T. Lee M.D., Ph.D. Founder
Dr. Danny Reinberg Founder
Ms. Esther P. Rajavelu CFO & Treasurer
Mr. Mel Hayes Chief Operating Officer
Mr. Gregory Tourangeau Controller & Principal Accounting Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.2789
Price-to-Sales TTM: 26.6208
IPO Date: 2019-07-18
Fiscal Year End: December
Full Time Employees: 104
Back to stocks